VNDA Key Statistics, Chart & Performance
The current stock price of VNDA is 7.78 USD. In the past month the price increased by 10.67%. In the past year, price increased by 76.42%.
VNDA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to VNDA. When comparing the yearly performance of all stocks, VNDA is one of the better performing stocks in the market, outperforming 95.26% of all stocks.
VNDA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VNDA. While VNDA is still in line with the averages on profitability rating, there are concerns on its financial health.
VNDA Financial Highlights
Over the last trailing twelve months VNDA reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS decreased by -407.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.01% | ||
| ROE | -18.07% | ||
| Debt/Equity | 0.01 |
VNDA Forecast & Estimates
10 analysts have analysed VNDA and the average price target is 13.9 USD. This implies a price increase of 78.63% is expected in the next year compared to the current price of 7.78.
For the next year, analysts expect an EPS growth of -751.86% and a revenue growth 9.44% for VNDA
VNDA Ownership
About VNDA
Company Profile
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 368 full-time employees. The company went IPO on 2006-04-12. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Company Info
VANDA PHARMACEUTICALS INC
Suite 300E, 2200 Pennsylvania Ave Nw
WASHINGTON WASHINGTON DC 20037 US
CEO: Mihael H. Polymeropoulos
Employees: 368
Phone: 12027343400
VANDA PHARMACEUTICALS INC / VNDA FAQ
What does VANDA PHARMACEUTICALS INC do?
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 368 full-time employees. The company went IPO on 2006-04-12. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
What is the stock price of VANDA PHARMACEUTICALS INC today?
The current stock price of VNDA is 7.78 USD. The price increased by 1.17% in the last trading session.
Does VNDA stock pay dividends?
VNDA does not pay a dividend.
How is the ChartMill rating for VANDA PHARMACEUTICALS INC?
VNDA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of VANDA PHARMACEUTICALS INC (VNDA)?
VANDA PHARMACEUTICALS INC (VNDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.42).
What is the expected growth for VNDA stock?
The Revenue of VANDA PHARMACEUTICALS INC (VNDA) is expected to grow by 9.44% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for VANDA PHARMACEUTICALS INC?
VANDA PHARMACEUTICALS INC (VNDA) currently has 368 employees.